The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

T Cell Receptor Based Therapy of Metastatic Colorectal Cancer (TCR-CRC-001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03431311
Recruitment Status : Terminated (Sponsor decision)
First Posted : February 13, 2018
Last Update Posted : June 13, 2019
Information provided by (Responsible Party):
Svein Dueland, Oslo University Hospital

Brief Summary:
T Cell Receptor Based Therapy of Metastatic Colorectal Cancer With mRNA-engineered T Cells Targeting Transforming Growth Factor Beta Receptor Type II (TGFβII)

Condition or disease Intervention/treatment Phase
Colorectal Cancer Biological: Adoptive Cell Therapy (ACT) Phase 1 Phase 2

Detailed Description:

Patients with advanced metastatic colorectal cancer who have no other effective treatment options will be offered the treatment. These patients have a poor prognosis, and there is a strong need for improved therapy.

The patients will be given adoptive cell therapy (ACT) with Radium-1 TCR+ T cells transiently redirected against the TGFβRII frameshift antigen which is expressed in MSI+ colon cancer. The first report on TCR therapy in colon cancer was targeting carcinoembryonic antigen (CEA) where some evidence of clinical response was seen, but the T-cell function may have been inhibited due to the necessity to resolve the severe colitis which occurred due to the presence of CEA in normal cells in the colon. This demonstrates the feasibility of T-cell therapy in metastatic colon cancer, but also the limitations of targeting CEA as an antigen.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Protocol for Treatment Under Hospital Exemption: T Cell Receptor Based Therapy of Metastatic Colorectal Cancer With mRNA-engineered T Cells Targeting Transforming Growth Factor Beta Receptor Type II (TGFβII)
Actual Study Start Date : March 8, 2018
Actual Primary Completion Date : June 12, 2019
Actual Study Completion Date : June 12, 2019

Arm Intervention/treatment
Experimental: Adoptive Cell Therapy (ACT)

The ACT will be administered as two intravenous (i.v.) injections of GMP TCR T cells per week for 6 weeks.

Escalating dose per week, from 1 x108 cells (week 1) to 2x109 cells (week 4 onwards) using a central venous catheter. The doses listed indicate the maximum number of T cells per injection at any given time point.

Biological: Adoptive Cell Therapy (ACT)
T cell receptor based therapy of metastatic colorectal cancer with mRNA-engineered T cells targeting mutant transforming growth factor beta receptor type II (TGFβII)

Primary Outcome Measures :
  1. Incidence, nature, and severity of adverse events graded according to NCI CTCAE v4.0 [ Time Frame: 2 years ]
    Incidence, nature, and severity of adverse events graded according to NCI CTCAE v4.0

Secondary Outcome Measures :
  1. Progression free survival (PFS) [ Time Frame: 2 years ]
    PFS defined as time from treatment to objective progression (as assessed by RECIST v1.1)

  2. Radiological response rate (ORR) [ Time Frame: 2 years ]
    ORR defined as the proportion of patients with an objective tumor response

  3. Overall survival (OS) [ Time Frame: 2 years ]
    OS defined as time from treatment to date of death from any cause

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with metastatic colon cancer which is MSI+ with the presence of the -1A deletion in TGFβRII gene, and positive for HLA-A02 genotype
  • Measurable disease
  • Female or male patients. Fertile females must have a negative pregnancy test before inclusion in the trial. Both fertile men and women must be ready and able to use highly effective methods of contraception, defined as use of oral, implanted, injectable, and mechanical or barrier products for the prevention of pregnancy during participation of the trial
  • Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 1
  • Age 18 years and older
  • Life expectancy of at least 3 months
  • Signed informed consent (by the subject or subject's legal representative) obtained before any trial-related procedures.
  • Adequate organ function, measured by pre-defined laboratory values

Exclusion criteria

  • Other metastatic malignancies
  • Any other anti-tumour treatment within 4 weeks prior to first administration of cells.
  • Steroid treatment, except substitution dose
  • Significant cardiac or other medical illness that would limit activity or survival, such as severe congestive heart failure, unstable angina or serious cardiac arrhythmia
  • Active infection requiring antibiotic therapy
  • Pregnancy or lactation
  • Known hypersensitivity to any of the components of the investigational product
  • Patients who test positive for hepatitis B, C, HIV or syphilis
  • Any reason why, in the opinion of the investigator, the patient should not participate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03431311

Layout table for location information
Oslo University Hospital
Oslo, Norway, 0379
Sponsors and Collaborators
Oslo University Hospital
Layout table for investigator information
Principal Investigator: Svein Dueland, MD PhD Oslo University Hospital
Layout table for additonal information
Responsible Party: Svein Dueland, Principal Investigator, Oslo University Hospital Identifier: NCT03431311    
Other Study ID Numbers: TCR-CRC-001
First Posted: February 13, 2018    Key Record Dates
Last Update Posted: June 13, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Svein Dueland, Oslo University Hospital:
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases